Shuttle Pharmaceuticals Holdings Inc.

About Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals is dedicated to developing novel therapies to increase cancer cure rates, prolong patient survival, and improve quality of life. Their mission focuses on enhancing the effectiveness of radiation therapy while minimizing side effects through innovative drug discovery and proprietary diagnostic technologies.

Products & Services

Ropidoxuridine:An orally available halogenated pyrimidine with strong cancer radiation sensitizing properties, currently in Phase II clinical stage.

HDAC Inhibitors:A portfolio of patented selective histone deacetylase inhibitors designed to modify the effects of ionizing radiation on cancer cells, with three pre-clinical candidate products.

PSMA-B:A diagnostic technology for prostate cancer patient management, developed through strategic collaborations and exclusive licensing.

PC-Rad Test:A predictive biomarker diagnostic test for prostate cancer patients considering elective radiation therapy, assessing risk for treatment success or failure.

Molecule.ai platform

Specialties

Cancer Therapy Radiation Therapy Sensitization Diagnostic Technologies for Prostate Cancer Drug Discovery Histone Deacetylase (HDAC) Inhibitors molecular discovery early-stage drug development AI-driven scientific workflows

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 2500000 MR: - FA: approximately $2.5 million FAN: 2500000	D: 2025-11-03 FD: 2025-11-03	1 investors
2	RT: Private Placement T: - FT: Private Placement	A: 4250000 MR: - FA: $4.25 million FAN: 4250000	D: 2025-06-24 FD: 2025-06-24	1 investors
3	RT: Private Placement T: - FT: Private Placement	A: 4250000 MR: - FA: $4.25 Million FAN: 4250000	D: 2025-06-20 FD: 2025-06-20	1 investors
4	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 5750000 MR: - FA: $5.75 million FAN: 5750000	D: 2025-03-13 FD: 2025-03-13	1 investors
5	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 5750000 MR: - FA: $5.75 million FAN: 5750000	D: 2025-03-12 FD: 2025-03-12	1 investors
6	RT: Public Offering T: - FT: Public Offering	A: 4500000 MR: - FA: 4.5 million FAN: 4500000	D: 2024-10-29 FD: 2024-10-29	1 investors
7	RT: Rights Offering T: - FT: Rights Offering	A: 4500000 MR: - FA: up to $4.5 million FAN: 4500000	D: 2024-02-13 FD: 2024-02-13	1 investors
8	RT: Private Placement of Senior Secured Convertible Note and Warrants T: - FT: Private Placement of Senior Secured Convertible Note and Warrants	A: 4300000 MR: - FA: 4.3 Million FAN: 4300000	D: 2023-01-12 FD: 2023-01-12	1 investors

Private Placement Latest

2025-11-03

$2.5M

1 investor (Pro only)

Private Placement 2025-06-24

$4.2M

Private Placement 2025-06-20

$4.2M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Christopher Cooper

Interim CEO, Director

Y

Yuying Liang

Chief Financial Officer

M

Mira Jung

Founder & Scientific Director

G

George Scorsis

Chairman

A

Adam Chambers

Director

A

Angel Liriano

Director

View 4 more team members with Pro

Unlock Full Team Directory

Recent News